Business
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment o
About this update from Journey Medical Corporation
[{"type":"image","alt":"Journey Medical Corporation","displaySize":"","headline":null,"caption":"Journey Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hjjUQ.iXZdhdLwOzj17HjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91}},"lazy":false},{"type":"text","content":"Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025","length":93,"tagName":"p"},{"type":"text","content":"Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase","length":101,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release), the Company’s recently launched treatment for the inflammatory lesions of rosacea in adults. This compares to 29% of commercial lives in May 2025. Journey Medical continues to execute on the launch of Emrosi, with expanded payer coverage anticipated to facilitate further growth in total prescription (TRx) demand. ","length":890,"tagName":"p"},{"type":"text","content":"“We are extremely pleased with the ongoing adoption of Emrosi by commercial payers, which is being driven by our targeted contracting strategy, increasing prescription demand, and strong clinical data demonstrating superior efficacy of Emrosi over the current standard of care,” said Claude Maraoui, Co-Founder, President, and CEO of Journey Medical Corporation. “Delivering cost-effective coverage for high-quality dermatologic medicines is a core priority for Journey Medical, and our strong progress with payers and our patient access program both help to ensure that pati...